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ABSTRACT 
 
Tumor metastasis is a complex multistep process. Among key steps that occur 
during metastatic spread are acquisition of tumor cell motility, intravasation of tumor 
cells into blood or lymphatic vessels and extravasation of tumor cells at distal sites. 
However, the precise mechanisms that govern these metastatic steps remain elusive. 
This thesis aimed to bridge the fields of tumor and vascular biology to provide new 
insights into the metastatic process. Results are presented indicating a role of the 
cytokine transforming growth factor beta (TGF-β) in activating breast cancer cells for 
dissemination through the lymphatic system through re-activation of a latent 
development process termed epithelial to mesenchymal transition (EMT). Furthermore, 
essential roles of the coxsackie-and adenovirus receptor (CAR) for lymph vessel 
development, and the sphingosine-1-phosphate receptor (S1PR1) for blood vessel 
stabilization are presented. We expect the findings to have impact on our understanding 
of the interface between tumor and vascular biology and to influence future strategies 
to target cancer metastasis.  
 In paper I, we present data identifying an essential role of CAR for normal 
development of lymphatic vessels in the mouse.  We show that genetic deletion of the 
CAR gene (Cxadr) from E12.5 during mouse development leads to subcutaneous 
edema, hemorrhage and embryonic death. The lymphatic vessels in CAR-deficient 
mice were dilated and structurally abnormal with the presence of gaps and holes at 
lymphatic endothelial cell-cell junctions. In addition, blood-filled lymphatics were 
observed in CAR-deficient mice suggesting an incomplete separation between the 
blood and lymphatic vascular systems. The data demonstrate that CAR plays a crucial 
role in the development of lymphatic vasculature in mice through formation of 
lymphatic endothelial cell-cell junctions. 
 In paper II, we demonstrate that S1PR1 plays critical role in suppressing 
angiogenesis and promoting vascular stability during mouse development. S1PR1 
signaling promotes cell-cell adhesion and prevents sprouting angiogenesis whereas 
S1PR1-deficiency leads to hypersprouting angiogenesis. These data suggest that S1PR1 
signaling might protect developing blood vessels from abnormal angiogenic signals 
through promotion of vascular stability. 
 In paper III, we show that TGF-β-induced EMT promotes chemotactic 
migration of tumor cells through the lymphatic system by mediating crosstalk between 
tumor cells and lymphatic endothelial cells through the chemokine receptor 7 (CCR7) 
and its chemokine ligand, CCL21. Reversal of EMT process through p38 MAPK 
inhibition inhibited tumor cell invasion in vitro and migration towards the lymphatics in 
vivo suggesting that p38 MAPK inhibition may be a useful therapeutic approach to 
inhibit tumor cell dissemination through the lymphatic system. 
 In paper IV, we describe development of a novel co-culture system to study 
tumor cell migration and interaction with lymphatic endothelial cells within a 3-
dimensional matrix component. This assay allows manipulation of tumor properties or 
matrix components and can be used as a platform to screen for pharmacological agents 
which inhibit tumor-endothelial interactions. 
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1 INTRODUCTION 
 
1.1 BREAST CANCER 
 
Breast cancer is the most common type of female malignancy and the most frequent 
cause of cancer-related death among women [1]. The primary cause of death in breast 
cancer, and in most other types of cancer, is metastatic spread of cancer cells to vital 
organs, rather than primary tumors. Therefore, unraveling the underlying mechanisms, 
which regulate breast cancer metastasis is important for future development of 
therapeutics drugs that can inhibit metastatic spread, and death in cancer.  
 
 
1.2 TUMOR METASTASIS 
 
 
 
Figure 1: Model of tumor metastasis. Metastasis involves multiple steps 
including detachment of tumor cells from primary site, intravasation, survival 
during the transit, extravasation and subsequently colonization at distal 
organs. Reprinted from Gupta and Massague, Cell 2006, with permission from 
Elsevier. 
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During tumor progression, tumor cells evolve through a combination of 
genetic alterations and diverse interactions with the tumor microenvironment and 
gain the ability to migrate, invade and metastasize. Tumor metastasis is process 
which involves a series of complex cascades that lead to the detachment of tumor 
cells from the primary tumor site; intravasation of tumor cells into blood or lymphatic 
vessels; and extravasation and growth at secondary sites [2,3] (Figure 1). In order for 
tumor cells to metastasize, tumor cells need to enter the blood or lymphatic 
vasculature. Still, tumor metastasis may be an inefficient process, with merely 0.01% 
or fewer circulating tumor cells could form metastases [4,5,6]. Metastatic tumor cells 
might need to express specific genes to be able to colonize different distant sites 
during metastasis [7,8,9,10,11]. Identification of mechanisms that regulate tumor cell 
trafficking in and out of lymphatic and blood vessels is crucial to control the 
metastatic process. 
 
 
1.2.1 Blood and lymphatic metastasis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Pathways for metastasis. (1) Tumor cells might traffic towards the 
lymphatics without entering the blood vessels and subsequently end up in venous 
circulation. (2) Tumor cells might intravasate into the blood and lymphatic vessels to 
metastasize to distal organs. Reprinted from Wong and Hynes, Cell Cycle, 2006. 
 
Lymphatic fluid from peripheral tissues is transported to lymph nodes where it 
is filtrated and collected for further transport via the thoracic duct or the right 
lymphatic duct, and directly drained into the subclavian vein (Figure 2). Thus, no 
matter whether tumor cells disseminate directly into blood vessels, or via the 
lymphatic system, they will eventually end up in venous circulation [12] (Figure 2). It 
has remained a challenge to determine whether tumor cells actively chose to migrate 
via lymphatic or blood vessels, or whether this is a random process. . Numerous 
studies have shown that most carcinomas spread via lymphatic dissemination [13]. 
For example, carcinomas and melanomas are often found to develop LN metastases. 
LN metastasis is an important parameter used for tumor staging and prognosis. 
Patients diagnosed with LN metastases possess high risk of having, or developing 
distal metastases. Tumor cells often invade the draining LN and subsequently to the 
distal LNs [14]. Tumor cells are likely absent at distal LNs if the draining LN 
remained uninvaded [14]. The presence of CTC in the blood and tumor cells in bone 
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marrow in patients is another important prognosis factor and indicator of distal 
metastases and has been associated with poor clinical outcome for cancer patients 
[14,15,16,17].  
 
 
1.2.2 Lymphatic metastasis: role of tumor lymphangiogenesis and 
chemotactic migration 
 
Histopathological analyses of human biopsies often show invading tumor cells 
or formation of new lymphatic capillaries towards surrounding tumor stroma and 
peritumoral lymphatics [14]. Malignant tumor cells have been shown to secrete 
various lymphangiogenic growth factors to stimulate lymphangiogenesis and 
lymphatic metastasis [18]. Studies have shown that lymphangiogenic growth factors 
such as VEGF-A, VEGF-C, VEGF-D and PDGFBB play a crucial role in promoting 
tumor lymphangiogenesis [19,20]. In addition to this, experimental evidence also 
suggested that active interactions between tumor cells and LEC might be required for 
lymphatic metastasis [21]. Skobe et al. showed that interaction between tumor cells 
and LEC can enhance tumor cell invasion into the lymphatics. VEGF-C secreted by 
the tumor cells can activate LEC and facilitate tumor cells transendothelial migration 
in human breast cancer [22]. 
 
It is suggested that migration of metastatic tumor cells is not random and that 
various types of cancer have specific metastasis pattern. More recent results indicate 
that tumor cells, similar to immune cells, may take advantage of certain CCs and 
CCRs during metastasis [23]. CCs are a superfamily of small peptides produced by 
various cells in the body promoting directional migration of cells expressing 
appropriate CCRs. Different tumor cells have been shown to express distinct CCRs 
subsets. These tumor cells may respond to chemotactic and invasive forces generated 
by CCs secreted by specific target destinations [24]. Among the CC/CCR pair that 
has been suggested to be an important mediator of breast cancer metastasis towards 
the lymphatic is CCL21/CCR7 [24]. CCR7 has been implicated in LN metastasis in 
various cancers [25,26]. Notably, CCR7 is also involved in the trafficking of dendritic 
cells (DCs) to LNs during inflammation [27]. This is supported by the findings that 
activated DCs of CCR7-deficient mice have impaired migration capacity towards the 
draining LNs [27]. Therefore, it is tempting to speculate that tumor cells may exploit 
a DC route of LN homing for metastasizing to the lymph. In addition, tumor cells 
might have more accessibility to the lymphatic vessels due to its ‘leaky’ structure. 
Unlike blood vessels which have continuous ‘zipper-like’ junctions between ECs, 
lymphatic vessels have semi-open,  discontinued ‘button-like’ junctions between ECs 
[28] suggesting that tumor cells may take advantage of this and use a similar 
mechanism of entry into the lymphatics as DCs.  
 
 
1.3 DEVELOPMENTAL ANGIOGENESIS  
 
The development of blood vasculature involves multistep process such as cell 
proliferation, differentiation, migration and changes in ECM. These process is being 
tightly controlled and regulated [29]. Firstly, the mesoderm derived endothelial 
precursors (angioblasts) will form a primitive network of tubular endothelial structure 
through a process called vasculogenesis [30]. The primitive vasculature is then being 
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remodeled into hierarchical network of small and large vessels through a process 
known as angiogenesis which involves sprouting, branching and pruning [30,31] 
(Figure 3). Under physiological conditions, sprouting angiogenesis is restricted to 
wound healing and reproductive cycle. Angiogenesis also occurs during pathological 
conditions such as during tumor progression, chronic inflammation and vascular 
diseases [32]. Angiogenesis is predominantly being mediated by VEGF-A through its 
cognate receptorVEGFR-1 and VEGFR-2, (also known as FLT1 and FLK1) [33]. 
VEGF co-receptor, NRP, NRP1 and NRP2 enhance VEGFR-2 activity [34].  Mice 
lacking VEGF-A, FLT1 and FLK1 expression died between E8.5 and E9.5 due to 
vascular defects [35]. Sprouting angiogenesis ceases to allow neovessel stabilization 
after the vasculature network reaches sufficient size and configuration [36]. Neovessel 
stabilization is achieved through maturation process which is mediated through the 
recruitment of mural cells and pericytes to cover the developing endothelial tubes 
[37,38]. Among the molecules which has been shown to be important for the 
recruitment of these cells to vessels wall is S1PR1 which binds to S1P [39,40]. S1P is a 
sphingolipid produced by erythrocytes, platelets and EC. High concentration of S1P 
can be found in blood serum and S1P is known to induce cell proliferation, migration 
and adhesion [41,42,43,44]. Several in vitro analysis also suggest that S1P has a pro-
angiogenic role [43,45]. S1P receptor signaling is essential in the regulation of vascular 
permeability, recruitment of mural cells, trafficking of lymphocytes, inflammation and 
cardiac function [44]. S1P interacts with its cognate receptor, S1PR1 which is 
expressed abundantly in differentiating EC [46]. S1PR1 knockout mice had severe 
hemorrhage and died between E12.5-E14.5 [47]. The process of vasculogenesis and 
angiogenesis was normal in S1PR1 knockout mice. However, these mice exhibited 
defects in vascular maturation due to lack of mural cells coverage on the endothelial 
tubes [40,43,47]. 
 
 
 
Figure 3: Development of blood vasculature. Angioblasts are derived from 
mesoderm cells. These cells form lining of the blood vessels through a process called 
vasculogenesis. The primitive vasculature is being remodeled into hierarchical 
network of small and large vessels through angiogenesis which involves sprouting, 
branching and pruning. Reprinted from Oliver, Nature Reviews Immunology, 2004, 
with permission from Nature Publishing Group. 
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1.4 DEVELOPMENTAL LYMPHANGIOGENESIS AND TUMOR 
LYMPHANGIOGENESIS 
 
The lymphatic system plays crucial roles in normal and disease conditions. 
Lymphatic system regulates tissue homeostasis by re-circulating fluid and cells [48] 
and involves in fat metabolism by absorbing lipid from the gastrointestinal tract [49]. 
During inflammation, lymphatic system mediates the trafficking of immune cells 
from tissues to lymph nodes [50]. Lymphatic system has been shown to be the 
primary route for lymphogenic spread of metastatic tumor cells [48]. Mutation in one 
of allele of lymphatic master regulator, Prox-1 leads to late-onset obesity in mice 
[51]. Lymphatic dysfunction causes lymphedema [52] as well as defects in blood 
pressure regulation during excessive salt intake [53].  
 
The mammalian lymphatic vasculature is derived from the veins [54]. This is 
support by the findings that Tie2-Cre;COUP-TFII
f/f
 conditional knockout mouse 
embryo has very few or virtually no LEC due to the absence of the vein endothelial 
cells [55]. Therefore, lymphatic vasculature only starts to develop from embryonic 
veins after the formation of the blood vasculature [56]. Venous endothelial cells 
differentiate into LEC and start to express LEC-specific markers such as: Prox-1, 
LYVE-1, vascular endothelial growth factor receptor-3 (VEGFR-3) and podoplanin at 
midgestation [57,58,59,60]. At around E9.5, transcription factors SOX18 induces 
lymphatic-lineage master regulator, Prox-1 expression in distinct subpopulations of 
the anterior cardinal vein [55]. These Prox-1-expressing vein endothelial cells acquire 
LEC fate and start to bud from the vein under the influence of vascular endothelial 
growth factor (VEGF) –C to form lymph sacs. As LECs migrate from the lymph sacs, 
the developing lymphatic vasculature should be separated by from the blood 
vasculature to form two independent circulation systems (Figure 4). It has been 
shown that expression of Slp 76, Syk, Plcg2 and podoplanin is important for the 
separation of blood and lymphatic vasculature [54,61,62,63]. After differentiation and 
maturation steps, LECs sprout and migrate from the lymph sacs to develop into a 
hierarchical network of lymphatic vessels [54,57,59,64].  
 
 
 
Figure 4: Development of lymphatic vasculature. (A) Distinct populations of EC 
from the vein acquired LEC fate and aggregate to form primary lymph sacs under the 
influence of VEGF-C produced by mesodermal cells. Further sprouting from the 
lymph sacs produces a hierarchical network of lymphatic vessels. Collecting 
lymphatic vessels have SMCs coverage. Reprinted from Schulte-Merker, Sabine and 
Petrova, JBC 2011. 
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1.4.1 Lymphatic junction proteins 
 
The mature lymphatic vasculature consists of blind-ended initial lymphatic 
capillaries and larger collecting lymphatic vessels. Lymphatic capillaries are thin wall 
vessels which lack pericytes and basement membrane coverage [54,65]. Lymphatic 
capillaries are composed of single layer of LEC and have unique junction 
organization where oak leaf-shaped endothelial cells are interconnected by 
discontinuous button-like junctions at the site of fluid entry [28] (Figure 5). 
Lymphatic vessels are connected to the ECM through anchoring filaments. 
Lymphatic anchoring filaments extend under high interstitial pressure. As a 
consequence, LEC junctions open and fluid enter into the lymphatic vessel [66,67]. 
The larger collecting lymphatic vessels have continuous zipper-like junctions similar 
to those of blood vessels [28] (Figure 5). Both button-like and zipper junctions 
express VE-cadherin and tight junctions including: occludin, JAM-A, claudin-5, ZO-
1 and endothelial cell-selective adhesion molecule. Transcriptional profiling of 
isolated lymphatic endothelial cells also showed that LEC expressed junctional 
proteins such as PECAM-1 (also known as CD31), VE-cadherin, JAM-A, occludin 
and CAR [28,68,69,70,71,72].  
 
 
 
 
 
Figure 5: Buttons and zippers in lymphatic vessels. (A) Initial lymphatics have 
discontinuous button-like junctions while collecting lymphatics have continuous 
zipper-like junctions. Reprinted from Baluk and Fuxe et al., 2007 JEM. 
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1.4.2 CAR 
 
CAR was first identified as a cellular receptor for coxsackie B viruses and type C 
adenoviruses. CAR is a family of immunoglobulin-like surface molecule which 
appears to mediate cell-cell contact and adhesion [73,74]. In polarized epithelial cells, 
CAR co-precipitates with ZO-1 [73] and other tight junction components [75]. 
Epithelial tight junctions control the flow of ions and macromolecules across the 
epithelium. Overexpression of CAR leads to homotypic cell adhesion and inhibit the 
transepithelial movement of ions and macromolecules [73]. It has been shown that 
CAR expression is down-regulated soon after birth and predominantly expressed at 
tight junctions of epithelial cells [76]. During development, CAR expression is 
indispensable for heart development. CAR is present at the intercalated discs of 
cardiomyocyte to mediate intercellular contract. CAR deletion in mice leads to 
embryonic lethality at around E11.5-E13.5 due to functionally impaired 
cardiomyocyte [77,78]. Cardiomyocyte-specific deletion of CAR in mice after E11 
does not lead to embryonic lethality, suggesting CAR expression is crucial within a 
specific time frame during heart development [79]. Recently, it has been shown that 
CAR is expressed by LEC [72] and that CAR plays important roles for LEC cell 
adhesion, migration, tube formation and the control of vascular permeability [72]. 
 
 
1.5 EMT 
 
 
Figure 6: EMT model. During EMT process, tumor cells lost their polarity and cell-
cell contact. Activation of EMT-Tfs enhances tumor cell migration and invasion and 
subsequently leads to tumor cell dissemination to distal organs. Reprinted from 
Peinado, Olmeda and Cano, Nature Reviews Cancer, 2007, with permission from 
Nature Publishing Group. 
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EMT is a process in which polarized epithelial cells undergoing profound 
morphological transformation into highly migratory and invasive mesenchymal-like 
cells [80] (Figure 6). EMT is a reversible process and involves a cascade of genetic 
programs in epithelial cells which eventually leads to loss of apical-basal polarity and 
cell-cell interactions due to the activation of EMT-Tfs such as Snail, Twist, Zeb, Slug 
and others [81,82,83,84,85]. Cells undergoing EMT has increased deposition of ECM 
proteins. Activation of integrin signaling by ECM in these cells leads to formation of 
focal adhesion complexes which enhance cell migration [86]. Initially, EMT was 
identified as a key process during embryogenesis for generation of tissues and organs. 
Later, researchers found that EMT also occurs during physiological and pathological 
conditions such as wound healing, fibrosis and cancer [80,87]. EMT has been 
suggested to be involved during tumor progression to facilitate the dissemination of 
tumor cells from primary site to distal organs [88]. EMT induction in tumor cells leads 
to the acquisition of invasive and metastatic properties [89].Similar to the EMT process 
occurred during development, EMT during tumor progression is a dynamic and 
transient event [90].  
 
 
1.5.1 TGF-β, TGFβ signaling and TGF-β-induced EMT 
 
TGFβs are polypeptides that governs wide range of cellular processes such as 
cell motility, cell growth and differentiation, production of ECM and immune 
functions [91,92]. TGFβ acts as tumor suppressor during early stage of tumorigenesis. 
At this stage, tumor cells response to TGFβ with growth inhibition, apoptosis and cell 
cycle arrest. However, at later stage during tumorigenesis, Tumor cells acquire 
aberrant TGFβ signaling or become unresponsive to TGFβ stimulation. Thus, TGFβ 
acts as tumor promoter through promotion of cell survival, proliferation, EMT and 
others [93]. TGFβ expression has been correlated with invasion and metastasis in 
human breast cancers [94,95].  
 
There are three different TGFβ isoforms with different functions: TGF-β1, 
TGF-β2 and TGF-β3 [92]. All TGFβ isoforms utilize similar receptor system to 
transduce signaling.  TGFβ has three receptors: TGFβ type I (TGFβRI), TGFβ type II 
(TGFβRI) and TGFβ type III (TGFβRIII) receptors [92]. TGFβ signaling includes 
Smad-dependent and Smad-independent pathway (Figure 7). Smad-dependent 
pathway involves binding of TGFβ ligand to the heterotetrameric complex of 
TGFβRI and TGFβRII. Activation of TGFβRI phosphorylates R-Smads such as 
Smad2 and Smad3. Binding of R-Smads to Co-Smad translocate the resulting 
complex into nucleus and leads to transcription activation or repression [96,97] 
(Figure 7). In addition to Smad-dependent pathway, TGFβ can induce Smad-
independent pathways which do not involve activation of Smad proteins. Among the 
Smad-independent pathways which can be activated by TGFβ include: p38, MAPK, 
Rho-like GTPase and PI3K/Akt [97]. Smad-independent pathways can be activated 
by receptor interacting proteins as well as non-Smad substrates of the receptor 
kinases [97] (Figure 7). 
 
TGF-β1 is a potent inducer of EMT [98] and is produced by various cells 
within the tumor environment [89]. TGFβ-1 can also be expressed in tumor cells and 
act in an autocrine manner [99]. In TGFβ-sensitive or moderately sensitive cells, 
TGF-β stimulation alone is sufficient to induce an EMT phenotype [100]. Smad 
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signaling is a crucial mediator of TGFβ-induced EMT [101]. EMT induction is 
enhanced by Smad3/4 whereas dominant-negative Smad3 inhibits TGFβ-induced 
EMT in NMuMG cells [102,103]. TGFβ can also work in concert with other 
signaling pathways such as Ras, Wnt, Hedgehog and Notch to induce EMT [84]. 
Epithelial cell polarization and barrier integrity is normally regulated by adherens and 
tight junction components. During TGFβ-induced EMT, these junction proteins are 
down regulated resulting in loss of cell polarization, cell-cell contacts and context-
dependent cell growth [104]. In addition, mesenchymal proteins like vimentin, N-
cadherin and α-smooth muscle actin are upregulated during EMT resulting in 
cytoskeleton remodeling and a highly motile, fibroblast-like mesenchymal phenotype, 
conferring cells with migratory and invasive properties [105]. Several EMT-
promoting transcription factors have been identified to promote repression of junction 
proteins [10,106,107]. Among these transcription factors, SNAIL1 has been shown to 
form transcriptional complex with SMAD3/4 to repress junction proteins during 
TGF-β-induced EMT [108]. Loss of adheren and tight junction proteins is a hallmark 
of EMT and is a characteristic feature of invasive human carcinomas [97,108,109]. 
TGF-β signaling has been implicated in tumor progression and metastatic processes 
[110]. However, it is unclear whether TGF-β-induced EMT could contribute to 
lymphatic metastasis. 
 
 
Figure 7: TGF-β signaling. Binding of ligand to the heterotetrametic complex of 
type I and type II TGF-β receptor initiate TGF-β signaling. TGFβ can activates both 
Smad-dependent and Smad-independent pathways. Smad-depedent pathway involves 
translocation of Smad complexes into nucleus to activate or repress gene 
transcriptions.  Smad-independent pathways which can be activated by TGFβ include 
p38, JNK, Akt, MAPK and PI3K. 
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1.6 METHODS TO STUDY TUMOR CELL MIGRATION AND INVASION 
 
Tumor cell migration and invasion are complex process which involves tumor 
interaction with stromal components and surroundings tissue architecture. Tumor cell 
migration and invasion is an essential step in tumor metastasis. In order to metastasize, 
tumor cells need to change their adhesion properties, migration and the ability to 
degrade ECM components [111,112]. Owing to the fact that it is very difficult to study 
tumor cell invasion and migration in vivo, several in vitro invasion assays have been 
developed over the years to recapitulate tumor cell invasion and migration in vivo 
[111]. Scratch or wound healing assay is a simple assay which is being developed to 
study the capacity of tumor cells to migrate towards an artificially created wound [112] 
(Figure 8). The most widely used Boyden chamber chemoinvasion assay is being used 
to evaluate the invasion potential of tumor cells based on its capacity to penetrate 
through a reconstituted ECM barrier coated on a porous membrane towards a 
chemoattractant gradient at the lower chamber [113] (Figure 8). Later, tumor cells 
transendothelial assay has been developed based on modification of Boyden chamber 
assay to study interaction of tumor cells with endothelial cells [114,115,116,117,118] 
(Figure 8). In this assay, a monolayer of endothelial cells are cultured on the porous 
membrane and coated with ECM. Invasion capacity of tumor cells is determined by the 
ability of tumor cells to transmigrate across the ECM and endothelial monolayer. 
However, these assays are oversimplified, do not mimic the physiological conditions 
during tumor invasion and are not able to elucidate detailed mechanisms of tumor cell 
invasion such as individual or collective invasion [119]. Since assessment of these 
tumor cells behaviors is crucial in order to provide us with a better understanding on 
how metastatic tumor cells disseminate, an improved in vitro migration and invasion 
assay needs to be developed. 
 
 
 
Figure 8: Migration and invasion assays. (A) Scratch or woundhealing assay is 
used to study the migration capacity of cells. A ‘wound’ is created by scratching the 
surface of a monolayer cells. Capacity of cells to migrate towards the wound is being 
evaluated. (B) Chemoinvasion assay is used to study the invasion capacity of cells 
within a matrix towards a chemoattractant gradient. (C) Transendothelial assay is 
used to study the ability of cells to penetrate through an EC monolayer.  
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2 AIMS OF STUDY 
 
The specific aims are: 
 
 To study whether CAR expression is required for development of lymphatic 
vessel in vivo and the consequences of CAR-deletion in the development of 
lymphatic vasculature in vivo 
 
 To investigate the role of S1P1R in sprouting angiogenesis 
 
 To study whether TGF-β-induced EMT plays a role in breast cancer cells 
dissemination towards the lymphatic vessels and how TGF-β-induced EMT 
affects the migratory behavior of tumor cells towards the lymphatic in vitro and 
in vivo 
 
 To establish a novel 3D coculture assay which allows study of tumor cell 
migration/invasion and interaction with LEC 
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3 RESULTS AND DISCUSSION 
 
3.1 PAPER I 
 
Essential role of Coxsackie-and Adenovirus Receptor (CAR) in the development 
of the lymphatic system in mice  
 
CAR is a tight junction-associated cell adhesion molecule and being expressed 
predominantly at in epithelial cells in adult tissues. However, during development high 
levels of CAR expression is detected in the heart and brain. CAR is essential for heart 
development and localizes to intercalated discs in cardiomyocytes [79]. Genetic 
deletion of the CAR gene specifically in the heart caused embryonic death at E11 [79]. 
Recently, it was reported that CAR is expressed in lymphatic endothelial cells (LEC) 
and that it plays a role in regulating LEC migration and tube formation, in vitro [72]. 
However, it has not been clear whether CAR plays a role in formation of the lymphatic 
vasculature in vivo.  
 
In paper I, we aimed to uncover the role of CAR in the development of the 
lymphatic system in mice. To study this, we generated a tamoxifen-inducible whole-
body deletion of Cxadr mice (referred as cKO mice). By administering tamoxifen to 
pregnant mice we were able to delete the CAR gene (Cxadr) in the mouse embryos at 
E12.5, which was chosen as a time point since Cxadr deletion at E11 caused embryonic 
death due to heart abnormalities. We found that deletion of Cxadr from E12.5 caused 
subcutaneous edema, hemorrhage and embryonic lethality at around E16.5. However, 
the hearts appeared normal in these mouse embryos. This suggested that CAR might be 
important for the development of other parts of the cardiovascular system. Analysis of 
the subcutaneous blood and lymphatic vessels by whole-mount skin preparation of the 
wild type littermates revealed that CAR was being expressed in the lymphatic vessels 
but not blood vessels at E14.5-E16.5. CAR expression was localized cell-cell junctions 
between lymphatic endothelial cells, where it co-localized with CD31 and LYVE-1. 
However, we failed to detect any CAR expression in the lymphatic vessels in the adult 
mouse skin. This suggested that CAR could play a critical role in lymphatic vessels 
during a specific time window during development, when lymphatic endothelial cell-
cell junctions are established and lymphatic vessels are formed. However, as the 
lymphatic system is formed and eventually matures into a network of vessels CAR is 
no longer needed. It was recently reported that loss of tight junction-associated 
molecules may be overcome and partially compensated in vivo [120]. Based on this, it 
is tempting to speculate that CAR might possess redundant but crucial role in lymphatic 
endothelial cell-cell junction formation during specific time window and might be 
compensated or taken over by other junction proteins after the specific time window.  
 
We found no difference in distribution of the blood or lymphatic vessels in cKO 
and control embryos. However, the structure of the lymphatic vessels in cKO embryos 
was abnormal and dilated compared to the lymphatic vessels of the control embryos. 
We observed presence of gaps or holes localized at the lymphatic endothelial cell-cell 
junctions in the lymphatic vessels of the cKO but not in the lymphatic vessels of the 
control embryos. Further investigation of the subcutaneous lymphatic vessels by using 
electron microscopy showed that the integrity of the lymphatic vessels was being 
disrupted in the cKO embryos. There were regions of the lymphatic vessel luminal 
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surface that lacked LEC coverage in the cKO embryos while lymphatic vessel luminal 
surface was intact in the control embryos. Together, these data implied a role of CAR 
in the formation of lymphatic endothelial cell-cell junctions. CAR-deficient caused 
irregular lymphatic endothelial cell-cell junction formation and eventually loss of LEC. 
These data were in line with previous findings by Vigl. et al showing that knockdown 
of CAR in LEC impaired the formation of lymphatic endothelial cell-cell junction in 
vitro [72].  
 
Immunostaining with a marker for erythrocytes, TER-119, showed the presence 
of erythrocytes inside blood vessels but not in the lymphatic vessels in the control 
embryos. However, we detected the presence of erythrocytes in the lymphatic vessel in 
the cKO embryos. As blood-filled lymphatic vessels might indicate non-separation 
phenotype [62,63,64], this suggested that CAR-deletion might lead to defect in the 
separation of lymphatic vessels from the blood vasculature during development. We 
found that cKO embryos phenotype was reminiscent of podoplanin knockout mice, 
which also displayed a blood-filled lymphatic phenotype [63]. Similar to CAR 
expression, podoplanin was exclusively expressed in lymphatic, but not in blood 
vessels. In addition to podoplanin, depletion of Syk, SLP-76, kindlin-3 had been 
reported to contribute to non-separation phenotype. Recent studies revealed a new role 
for platelets in the formation of lymphatic vessels during development. Interaction 
between LEC and platelets was required for proper closure of the shunt between 
cardinal vein and the lymph sacs to form two separated circulation system [63]. 
Podoplanin, Syk, SLP-76 and kindlin-3 were important for platelets to function 
properly [121]. Since CAR expression recently was identified in human platelets [122], 
we speculate that loss of CAR might disrupt the interaction between LEC and 
circulating platelets, resulting a non-separation. It would be interesting for the future to 
this, which could be done by deletion of Cxadr in LEC and platelets. Further 
examination of blood-filled lymphatic in cKO embryos showed the erythrocytes were 
leaking out to the perivascular space from gaps of the defective lymphatic vessels, 
causing regions of hemorrhage. 
 
In conclusion, we found that CAR plays a critical role in the development of 
lymphatic system in mouse. CAR-deletion between E12.5-E15.5 lead to edema and 
hemorrhage due to structurally abnormal and defective lymphatic vessels. Our data 
suggest that CAR is important both for the formation of lymphatic endothelial cell-cell 
junctions, and for the separation of blood and lymphatic vasculature. For future studies, 
it would be interesting to investigate whether CAR expression is re-activated and 
possibly plays a role in the formation of new lymphatic vessels during pathological 
lymphangiogenesis, which is a characteristic feature of both chronic inflammatory 
diseases and cancer.  
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3.2 PAPER II 
 
The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by 
regulating the interplay between VE-Cadherin and VEGFR2 
 
 S1P is a sphingolipid metabolite produced by erythrocytes, platelets and EC. 
S1P acts via its cognate receptors, S1PR1-5. It is reported that EC expressed S1PR1-3 
[123]. S1P receptor signaling is critical in the regulation of vascular permeability, 
recruitment of mural cells, trafficking of lymphocytes, inflammation and cardiac 
function [44]. S1PR1, S1PR2 and S1PR3 triple knockout mice showed severe vascular 
phenotype [123]. However, S1PR1 appeared to be the most important receptor [123]. 
Similarly, depletion of S1P signaling through deletion of sphingosine kinase, Sphk1 and 
Sphk2 caused neural and vascular defects [124], implying S1P/S1PR1 signaling might 
be critical for the development of vasculature. 
 
 In paper II, we demonstrate that S1PR1 plays critical role in suppressing 
angiogenesis and promoting vascular stability in the endothelium by using in vivo, ex 
vivo and in vitro experimental model system.  
 
 My part of this project was to performed functional studies with mouse 
microvascular endothelial cells, MS-1 in vitro to uncover the role of S1PR1 in 
sprouting angiogenesis. We used well established fibrin bead assay [125] to study the 
role of S1PR1 in sprouting angiogenesis in vitro. We found that VEGF-A promoted 
sprouting of MS-1 cells. However, VEGF-induced angiogenic effect was inhibited by 
S1PR1 agonist, SEW2871 and S1P. Stimulation of SEW2871 and S1P on MS-1 
produced less but solid sprouts. In contrast, S1PR1-specific antagonist, (R)-W146 
further enhanced the effect of VEGF-dependent sprouting, causing hypersprouting 
where EC detached from the bead and scattered within the fibrin matrix, suggesting 
S1PR1 might affect endothelial cell-cell adhesion. The effect of (R)-W146 on sprouting 
can be inhibited by using VEGFR2 inhibitor SU5416, suggesting VEGF-dependent 
angiogenic sprouting effect of S1PR1 inhibition. Because of inhibition of S1PR1 
caused EC scattering, we suspected that S1PR1 might promote sprouting angiogenesis 
through regulating endothelial cell-cell adhesion. VE-cadherin has been shown to be a 
target for S1P signaling in vitro. Stimulation of S1P on EC caused increased VE-
cadherin level [126]. We then induced deletion of VE-cadherin in endothelial cells in 
the mice. We observed hypersprouting phenotype and increase vascular density in the 
retina of endothelial cell-specific VE-cadherin-deficient mice which mimicked the 
S1PR1-deficient mice phenotype. We further found that S1PR1-deficient retinas had 
abnormal VE-cadherin staining pattern. Depleting S1PR1 by using siRNA approach 
caused loss of VE-cadherin in the EC junctions whereas S1P treatment increased VE-
cadherin expression level. We also found downregulation of VE-cadherin induced by 
VEGF can be stored by S1P or SEW2871, suggesting an opposing role of S1P and 
VEGF signaling in VE-cadherin regulation. Inhibition of VEGF signaling by sFlt1 and 
SU5416 had no effect on S1P-induced VE-cadherin expression, indicating regulation of 
VE-cadherin by S1P was independent of VEGF-induced responses. In contrast, (R)-
W146 exerted opposing effect on VE-cadherin regulation compared to S1P and 
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SEW2871. Data from zebrafish experiments showed that depletion of individual cdh5 
and s1pr1 using morpholinos caused massive angiogenic hypersprouting in the 
hindbrain in the embryos. Combination of cdh5 and s1pr1 morpholinos injection at low 
dose caused similar results with high dose of single morpholinos, indicating S1PR1 and 
VE-cadherin could work together.  To study whether S1PR1 and VE-cadherin could 
cooperate, we performed in vitro sprouting angiogenesis assay by using MS-1 cells in 
the presence or absence of VE-cadherin blocking antibody, BV13. Indeed, we found 
BV13 potentiated sprouting in MS-1, suggesting inhibitory role of VE-cadherin during 
sprouting angiogenesis [127]. The angiogenic sprouting and cell scattering effect 
caused by BV13 was further enhanced in the presence of (R)-W146. On the other hand, 
SEW2871 reversed the angiogenic sprouting and cell scattering effect caused by BV13. 
These data provided evidence that S1PR1 and VE-cadherin work in concert to restrict 
sprouting angiogenesis. Data from in vitro signaling experiments showed that S1PR1 
inhibits VEGFR2 signaling events. This suggested that suppression of S1PR1-
dependent angiogenic sprouting is linked to suppression of VEGFR2 signaling.  
 
In conclusion, our data suggested that S1PR1 signaling inhibit sprouting 
angiogenesis through regulation of junctional VE-cadherin stabilization and 
suppression of VEGFR2 signaling events.  
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3.3 PAPER III 
TGF-β-induced epithelial to mesenchymal transition activates breast cancer cells 
for lymphatic dissemination 
 
Metastasis is the major cause of death in human cancer. For tumor cells to 
spread to distal organs, they need to enter either blood or lymphatic vasculature. As 
lymph will eventually drains into blood [12], tumor cells that disseminate through the 
lymphatic system will end up in the systemic circulation. Owing to this, it is technically 
challenging to study how tumor cells disseminate through the lymphatic system. 
Understanding on how tumor cells gain access to the lymphatic system might lead to 
novel therapeutic interventions. 
 
Elevated level of TGF- secretion has been associated with poor prognosis and 
lymph node metastases in human cancers [91,128,129]. The tumor microenvironment 
is a rich source of TGF- [91]. As TGF- is a potent inducer of EMT process, we 
speculated that tumor cells undergoing TGF-1-induced EMT might gain capacity to 
migrate specifically towards the lymphatic vessels. To test our hypothesis, we used a 
mouse model of footpad injection to study migration capacity of EMT and non EMT 
cells towards the draining PLN in vivo. Footpad injection is an established method to 
study DC and tumor cells trafficking towards the LN [130,131]. Three isogenic cell 
lines exhibit different EMT phenotype ( Figure 9) and TGF responsiveness were used: 
(i) EpH4 cells, mouse mammary gland epithelial cells which response to TGF by 
growth inhibition but not EMT; (ii) EpRas cells, which is derived from EpH4 but has 
acquired Ras signalling and can undergo EMT with TGF stimulation and (iii) EpXT, 
which is stable EMT model system driven by both Ras and autocrine TGF signalling. 
An additional TGF-induced EMT model system, NMuMG cells were also used. In 
order to track migration of EMT and non EMT cells in vivo, we labelled EpH4, EpRas 
and EpXT cells with GFP-expressing lentivirus. Footpad injection showed that GFP-
labelled Two days after footpad injection, we detected the presence of GFP-positive 
EpXT cells in the draining PLN whereas no GFP-positive EpH4 cells can be detected. 
This suggested that EMT cells possessed significant enhanced migration capacity 
towards the draining PLN in vivo in comparison to non EMT cells. Reversal of EMT 
phenotype in EpXT cells by downregulating TGFRII expression level using shRNA 
approach impaired the migration capacity of EpXT cells towards the draining PLN, 
indicating the role of EMT in mediating migration capacity of tumor cells towards the 
LN in vivo. In contrast, TGF-1-induced EMT in EpRas cells enhanced migration 
capacity of EpRas cells towards the LN significantly compared to the untreated control. 
These data provide evidence that TGF-1-induced EMT might contribute to lymphatic 
dissemination of tumor cells. 
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Figure 9: EMT model systems. EpH4 cells cannot undergo EMT in response to TGF-
1. EpRas cells can undergo TGF-1-induced EMT and EpXT is a stable EMT model 
driven by Ras and autocrine TGF signalling.  
 
 
Because TGF-1-induced EMT can increase migration capacity of tumor cells 
in general, we wonder whether tumor cells underwent TGF-1-induced EMT could 
gain capacity to migrate towards the lymphatic in a directional manner. 
Immunostaining of EpH4 tumors showed that EpH4 cells appeared to be non-invasive 
and did not migrate towards blood or lymphatic vessels. Immunostaining of EpXT 
tumors revealed that EpXT cells displayed different morphology in different regions of 
tumor. In some regions, EpXT cells appeared to be invasive and elongated whereas in 
some regions, EpXT cells seems to be ‘round’ shaped and noninvasive. Interestingly, 
we found that blood vessels were evenly distributed and abundant in all regions of the 
EpXT tumors whereas lymphatic vessels were concentrated in the invasive areas of the 
EpXT tumors. High resolution confocal microscopy also showed that EpXT cells 
appeared to intravasate into lymphatic vessels in the invasive regions of the tumor. 
Based on this, we speculated that EMT cells might show preferential migration towards 
the lymphatic vessels. We therefore set out to investigate whether TGF-1-induced 
EMT promoted targeted migration towards lymphatic rather than blood vessels. 
Because it is technical challenging to study tumor cell migration in vivo, we developed 
a 3D tumor-EC coculture system (Figure 10), which is based on a previously 
established fibrin beads assay [125]. We demonstrated that GFP-labelled EpXT cells 
possessed significantly enhanced migration capacity towards the LEC than VEC while 
GFP-labelled did not migrate towards either VEC or LEC. TGF-1-induced EMT in 
EpRas cells enhanced migration capacity of EpRas towards LEC rather than VEC, 
suggesting tumor cells that undergo TGF-1-induced EMT gain the capacity to migrate 
in a directional manner towards lymphatic vessels.  
 
 
 
Figure 10: Tumor-EC coculture system. Fluorescently-labelled EMT / non EMT and 
EC cells are being coated on a microcarrier beads. Migration of EMT / non EMT cells 
towards VEC/LEC will be observed under fluorescent microscope. 
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Since CCR7 plays indispensable role in mediating lymphatic homing of 
immune cells [27] and has been associated with lymphatic metastasis in human cancers 
[24,25,26,132], we speculated that tumor cells underwent TGF-1-induced EMT  
might activates CCR7 expression through EMT process and this allow EMT cells 
migrate towards the lymphatic vessel in a directional manner. Indeed, CCR7 expression 
was upregulated in both stable and TGF-1-induced EMT model systems. In contrast, 
CCR7 expression level remained unchanged in TGF-1 treated on non EMT cells, 
EpH4, suggesting CCR7 induction in response to TGF-1 is coupled to EMT process. 
Chemoinvasion assays showed that both stable and TGF-1-induced EMT model 
systems invade more efficiently towards CCL21 gradient, a chemokine which is being 
secreted by LEC. Using a CCR7 neutralizing antibody, we further demonstrated that 
the invasion and migration of EMT cells towards CCL21 gradient and LEC was CCR7-
dependent in the chemoinvasion and bead invasion assay. We also found that the 
migration capacity of EpXT cells towards the draining PLN were significantly impaired 
when CCR7 expression was being silenced by using siRNA approach, suggesting a role 
of CCR7 in mediating migration of EMT cells towards the lymphatic in vitro and in 
vivo. We also observed upregulation of CCL21 expression in LEC upon TGF-1 
stimulation and upregulation of CCL21 expression in the lymphatic vessels of EpXT 
tumors compared to the EpH4 tumors. These results demonstrated that TGF-1 might 
mediate the directional migration of EMT cells towards the lymphatic vessels through 
CCR7/CCL21 signalling. 
 
We then investigated the underlying molecular mechanism which regulates 
CCR7 expression during TGF-1-induced EMT. We found that CCR7 expression was 
driven by AP-1 activators during TGF-1-induced EMT in NMuMG cells and can also 
be regulated by both Smad3 and p38 signalling. Based on this, we postulated that 
inhibition of JNK, Smad3 and p38 signalling in EpXT cells might reduce lymphatic 
dissemination through the reversal of EMT process and downregulation of CCR7 
expression. We found that inhibition of JNK signalling in EpXT cells has no effect on 
CCR7 nor E-cadherin expression whereas inhibition of Smad3 signalling in EpXT cells 
restored E-cadherin expression but did not affect CCR7 expression. Treatment of EpXT 
cells with the SB203580 reduced CCR7 expression and increased E-cadherin 
expression. This suggested that inhibition of p38 signalling was most potent in 
reverting EMT phenotype in EpXT cells. This might be due to the stable EMT 
phenotype in EpXT cells were driven by both TGF-1 and Ras signalling, which 
converge on p38 MAPK [133]. In addition, we also found that treatment of SB203580 
impaired the invasion capacity of EpXT cells towards CCL21 gradient in vitro and 
migration capacity towards the draining PLN in vivo. Since high level of p38 
expression has been associated with poor prognostic of breast cancers [134,135], our 
data suggested targeting p38 signalling might be a useful strategy to inhibit lymphatic 
dissemination of tumor cells. 
 
Our data from clinical breast cancer samples suggested a link between TGF- 
signalling, lymphatic vessel density and lymphatic node metastasis. This is in 
accordance with previous findings which showed correlation of lymphatic vessels 
density and p-Smad3 expression with lymphatic metastasis in breast cancer [136,137]. 
However, the average staining of Snail/Twist in E-cadherin positive cells was 
statistically no difference with a tendency to be higher in the LN+ group than the LN- 
group. In some tumor samples, we were able to detect the presence of some CCR7 
positive cells with low E-cadherin expression at the invasive front, suggesting tumor 
cells underwent EMT might express CCR7. However, we will need to further validate 
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this finding in more clinical samples. Certainly, it is of interest to be able to identify 
tumor cells undergoing EMT express CCR7 and correlate EMT markers expression in 
tumor cells with lymphatic vessels invasion in clinical settings, transgenic mouse model 
of breast cancer or xenograft mouse model. Since EMT might be a transient process 
[90,138], capturing of EMT in vivo might be a challenge.  
 
Our finding indicated that TGF-1 promotes chemotactic migration of tumor 
cells towards the lymphatic vessels through CCR7/CCL21 signalling by: (i) inducing 
CCR7 expression in tumor cells through EMT process and (ii) upregulating CCL21 
expression in LEC. We also provide evidence that inhibition of p38 MAPK can partly 
reverse the EMT phenotype of tumor cells and supress CCR7 expression, suggesting 
p38 MAPK inhibition might be a useful strategy to inhibit lymphatic dissemination of 
tumour cells.  
 
As discussed earlier, it is a major challenge to study lymphatic dissemination of 
tumor cells in vivo. However, with the recent advances in intravital imaging techniques 
and the availability of lymphatic vessel-specific fluorescent transgenic mouse, it is 
possible to utilize these tools to study how fluorescently-labelled EMT tumor cells 
disseminate to the lymphatic vessels or intravasate into the lymphatic vessels in vivo in 
greater detail. Additional tumor model such as mammary fatpad xenograft model can 
be used to investigate migration of EMT / non EMT cells towards the draining LN in 
the mammary fatpad. 
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3.4 PAPER IV 
A three-dimensional beads invasion assay to study tumor cell migration and 
interaction with lymphatic endothelial cells  
 
Tumor metastasis is a complex process, which involves tumor cell 
migration/invasion and tumor-endothelial interactions [139]. It is technically 
challenging and expensive to study these processes in vivo. Therefore, numerous assays 
have been developed to study tumor cell migration and invasion in vitro [111]. 
However, most existing in vitro assays have their own drawbacks. For example, scratch 
or wound healing assay is used to study tumor cell migration towards an artificial 
‘wound’. This assay only allows study of tumor cell migration in 2D, without the ECM. 
To date, the classical Boyden chamber assay is the most widely used to study tumor 
cell migration/invasion. In this assay, the migration/invasion capacity of tumor cells is 
being evaluated based on the ability of tumor cells to penetrate through the ECM 
barrier towards a chemoattractant gradient [111,113]. The classical Boyden chamber 
assay is then modified into transendothelial assay as a method to study the ability of 
tumor cells to migrate across the EC barrier [114]. However, these assays do not mimic 
the physiologic conditions and it is difficult to study tumor cell migration/invasion or 
tumor-endothelial interaction in a greater detail with the existing assays. 
 
In order to overcome these drawbacks in the existing migration/invasion assays, 
we developed a 3D beads invasion assay based on modifications of existing fibrin bead 
assay [125]. This 3D beads invasion assay allows one to study tumor cell migration and 
interaction with LEC. This assay can also be modified to use to study cell-cell 
migration/invasion or cell-cell interaction with different cell types. In this study, we 
used invasive and non-invasive tumor cells and LEC expressing different fluorescent 
proteins to study tumor cell migration/invasion towards LEC and tumor-LEC 
interaction. Tumor cells/LECs were coated onto a microcarrier beads and then 
embedded into a 3D fibrin ECM. The use of reconstituted ECM to study tumor cell 
migration/invasion was critical as ECM is the major constituent of the tumor 
microenvironment [140]. As fibrin is the main component of tumor stromal [141], we 
reasoned that the usage of fibrin matrix in this assay might partly mimic the 
physiological conditions during tumor cell dissemination. In addition, the ability of 
tumor cells to invade and metastasize was greatly influence by molecular interactions 
attributed by tumor cells, surrounding ECM and stromal cells [142,143].  
 
Our 3D bead invasion assay holds advantages over the conventional Boyden 
chamber and transendothelial assay. This assay allows high resolution, real-time 
imaging of tumor cell migration/invasion and tumor-EC interactions. 
Migration/invasion of tumor cells within the ECM matrix can be visualized in great 
detail under time-lapsed high resolution confocal imaging. This enables one to study 
how tumor cells migrate (e.g. single cell or clustered migration) and how tumor cells 
interact with other cell types in 3D.  This assay is easy to manipulate, as we can grow 
different type of cells on the beads, and study how cells migrate/invade and interact 
with various cell types. This assay might also be used as a screening platform to 
identify novel modulators of tumor cell migration/invasion or tumor-EC interactions 
through: (i) genetic manipulations through overexpression or knockdown of specific 
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genes in the target cells or (ii) treatment with different growth factors, small molecules 
inhibitors or neutralizing antibodies. We provided evidence that anti-CXCR4 
neutralizing antibody can block the migration of invasive tumor cells, EpXT cells 
towards the LEC which secreted SDF-1, a ligand for chemokine receptor, CXCR4. 
Different ECM such as type I collagen, matrigel or a mixture of different ECM 
components can be used to study the effect of different ECM components on tumor cell 
migration/invasion or tumor-endothelial interactions. 
 
In conclusion, we developed a 3D coculture beads invasion assay, which can be 
used to study cell-cell migration/invasion and cell-cell interaction. The 3D bead 
invasion assay mimics several aspects of in vivo tumor invasion. Unlike the 
conventional 2D invasion assay, our assay allows the study of: (i) tumor cells 
migration/invasion within a 3D ECM and (ii) how other cell type e.g. EC influence 
tumor cells migration/invasion or vice versa in this coculture system. This assay is 
inexpensive, easy to manipulate and might serve as a screening platform for potential 
drug candidates.  
 
Similar to the existing invasion/migration assay, this assay has some 
drawbacks. This assay is technically challenging and laborious. Some cells appear to be 
more difficult to attach or grow on the microcarrier beads compared to the ones used in 
this protocol. Because the embedded beads are randomly distributed within the matrix, 
the distance between beads could affect the outcome. To overcome this, one has to 
define a range of distance between beads coated with tumor cells and endothelial cells 
for quantification. 
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4 GENERAL CONCLUSION 
 
These studies contribute to better understanding of the underlying mechanisms which 
regulate:  
 
 
(i) Development of lymphatic vessels in mice. CAR played critical role for 
lymphatic vessel development. CAR-deficient lead to structurally abnormal 
and functionally impaired lymphatic vessels. CAR expression was crucial 
for formation of lymphatic endothelial cell-cell junction. Loss of CAR-
mediated adhesion at lymphatic cell-cell junction lead to presence of gaps or 
holes in the lymphatic vessels due to improper formation of lymphatic 
endothelial cell-cell junction. The presence of blood-filled lymphatic in 
cKO mice suggested that CAR might be involved in the separation of 
blood/lymphatic vasculature separation (Paper I). 
 
(ii) Vascular stability. S1PR1 played critical role in suppressing angiogenesis 
and promoting the vascular stability. S1PR1 signaling promoted cell-cell 
adhesion and prevented sprouting angiogenesis, suggesting S1PR1 
signaling might protect developing blood vessels from abnormal angiogenic 
signals through promotion of vascular stability (Paper II). 
 
(iii) Lymphatic dissemination of tumor cells. TGF-β-induced EMT induces 
CCR7 expression in tumor cells. Concomitantly, TGF-β also induces 
CCL21 expression in LEC, suggesting that TGFβ promotes chemotactic 
migration of tumor cells towards the lymphatic by mediating tumor-LEC 
crosstalk through the activation of CCR7/CCL21 signaling. Inhibition of 
p38 MAPK signaling caused reversion of EMT phenotype and loss of 
CCR7 expression in tumor cells and reduced dissemination of tumor cells 
towards the lymphatic vessels in vivo, suggesting p38 inhibition as a 
potential therapeutic strategy (Paper III).  
 
(iv) In addition, the co-culture system that we developed will be an alternative 
for tumor biologist to study cell migration and interactions within 3D. This 
assay can also be used as a platform to screen for pharmacological agents 
(Paper IV). 
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